Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.

"CONFLICTS OF INTEREST Guarantor of the article: Jeffrey F. Mather, MS. Specific author contributions: J.F.M. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors played a part in concept and design. J.F.M. performed data acquisition. All authors had a role in interpretation and drafting the manuscript. J.F.M. and R.L.S. performed statistical analysis. R.G.M. and J.F.M. wrote the manuscript, and all authors gave critical revision of the manuscript for important intellectual content. Financial support: None to report. Potential competing interests: None to report.Study HighlightsWHAT IS KNOWN?✓ Despite multiple trials that are currently underway to investigate the safety and efficacy of a large number of possible therapeutic agents, no drug to date has been shown to reduce COVID-19 mortality.✓ It has been postulated that famotidine's effect is achieved via its antagonism or inverse agonism of the histamine-2 receptor, inferring that the SARS-CoV-2 infection that results in COVID-19 is at least partially mediated by pathological histamine release.✓ As a histamine-2 receptor antagonist, famotidine is a therapeutic option in COVID-10–positive patient therapy.WHAT IS NEW HERE?✓ We describe a propensity-matched comparison of patients with COVID-19 treated with and without famotidine.✓ Famotidine use was significantly associated with a reduction in death and either death or intubation.✓ Famotidine users demonstrated lower levels of serum markers for severe disease in hospitalized patients with COVID-19."

"Financial support: None to report."